The financials
Harrow, Inc. by the numbers
Harrow, Inc. (HROW) reported revenue of $44M in Q1 2026 (quarter ended March 31, 2026), down 7.6% from the same quarter a year earlier. That came with a gross margin of 61% and net loss of $28M. For the full year FY2025, revenue was $272M (+36% year on year) and net income −$5.1M. Its largest product in 2026-Q2 was Product Sales Net at $71M, 100% of the disclosed total, just ahead of Other at 0.1%.
| Income statement | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $44M | $48M | −7.6% |
| Gross profit | $27M | $32M | −16% |
| Operating income | −$22M | −$11M | n/a |
| Net income | −$28M | −$18M | n/a |
| Diluted EPS | −$0.74 | −$0.50 | n/a |
| Product | Revenue | Share |
|---|---|---|
| Product Sales Net | $71M | 100% |
| Other | $90K | 0.1% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q2 2026Total $70.7M (+60%)
Product Sales Net grew +11% year on yearOther +5.9% year on year
Segment Latestquarter on quarteryear on year
- Product Sales Net$70.6M$70.6MQoQ +60%year on year +11%+60%+11%
- Other$90.0K$90.0KQoQ +23%year on year +5.9%+23%+5.9%
- Other--QoQ -year on year ---
Drug Manufacturers - Specialty & Generic
Ranks #26 of 28 by Smart Score